In this issue as usual we report regulatory actions taken around the world on grounds of safety issues, among them new restrictions in the use of rosiglitazone, and the market withdrawal of sibutramine. We also give you updates on the safety of several medicines.

The feature article in this issue gives you conclusions from working groups at the thirty-third meeting of representatives of national pharmacovigilance centres participating in the WHO Programme for International Drug Monitoring...